Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)

C. M L Van Herpen, M. E. Mauer, R. Mesia, M. Degardin, S. Jelic, C. Coens, J. Betka, J. Bernier, E. Remenár, J. S. Stewart, J. H. Preiss, D. Van Den Weyngaert, A. Bottomley, J. B. Vermorken

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background:The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck, showed an improved progression-free and overall survival (OS) with less toxicity when docetaxel (T) was added to cisplatin and 5-fluorouracil (PF) for induction and given before radiotherapy (RT). The impact of the addition of docetaxel on patients health-related quality of life (HRQOL) and symptoms was investigated.Methods:HRQOL was assessed at baseline, at end of cycle 2, and 4, 6, and 9 months after completion of RT using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and the EORTC QLQ Head and Neck Cancer-Specific Module (EORTC QLQ-HN35). The primary HRQOL scale was global HRQOL per protocol.Results: Compliance to HRQOL assessments was 97% at baseline, but dropped to 54% by 6 months. Data were analysed up to 6 months. There was a trend towards improved global HRQOL during the treatment period. At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm, but the low compliance does not allow to draw definitive conclusions. Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2, but to a limited extent.Conclusion:Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.

Original languageEnglish
Pages (from-to)1173-1181
Number of pages9
JournalBritish Journal of Cancer
Volume103
Issue number8
DOIs
Publication statusPublished - Oct 12 2010

Fingerprint

docetaxel
Head and Neck Neoplasms
Fluorouracil
Cisplatin
Quality of Life
Organizations
Research
Neoplasms
Radiotherapy
Therapeutics
Induction Chemotherapy
Deglutition

Keywords

  • head and neck cancer
  • HRQOL
  • symptoms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). / Van Herpen, C. M L; Mauer, M. E.; Mesia, R.; Degardin, M.; Jelic, S.; Coens, C.; Betka, J.; Bernier, J.; Remenár, E.; Stewart, J. S.; Preiss, J. H.; Van Den Weyngaert, D.; Bottomley, A.; Vermorken, J. B.

In: British Journal of Cancer, Vol. 103, No. 8, 12.10.2010, p. 1173-1181.

Research output: Contribution to journalArticle

Van Herpen, C. M L ; Mauer, M. E. ; Mesia, R. ; Degardin, M. ; Jelic, S. ; Coens, C. ; Betka, J. ; Bernier, J. ; Remenár, E. ; Stewart, J. S. ; Preiss, J. H. ; Van Den Weyngaert, D. ; Bottomley, A. ; Vermorken, J. B. / Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). In: British Journal of Cancer. 2010 ; Vol. 103, No. 8. pp. 1173-1181.
@article{86e640a4dc7747cea30ce4ef9e8e2a07,
title = "Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)",
abstract = "Background:The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck, showed an improved progression-free and overall survival (OS) with less toxicity when docetaxel (T) was added to cisplatin and 5-fluorouracil (PF) for induction and given before radiotherapy (RT). The impact of the addition of docetaxel on patients health-related quality of life (HRQOL) and symptoms was investigated.Methods:HRQOL was assessed at baseline, at end of cycle 2, and 4, 6, and 9 months after completion of RT using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and the EORTC QLQ Head and Neck Cancer-Specific Module (EORTC QLQ-HN35). The primary HRQOL scale was global HRQOL per protocol.Results: Compliance to HRQOL assessments was 97{\%} at baseline, but dropped to 54{\%} by 6 months. Data were analysed up to 6 months. There was a trend towards improved global HRQOL during the treatment period. At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm, but the low compliance does not allow to draw definitive conclusions. Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2, but to a limited extent.Conclusion:Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.",
keywords = "head and neck cancer, HRQOL, symptoms",
author = "{Van Herpen}, {C. M L} and Mauer, {M. E.} and R. Mesia and M. Degardin and S. Jelic and C. Coens and J. Betka and J. Bernier and E. Remen{\'a}r and Stewart, {J. S.} and Preiss, {J. H.} and {Van Den Weyngaert}, D. and A. Bottomley and Vermorken, {J. B.}",
year = "2010",
month = "10",
day = "12",
doi = "10.1038/sj.bjc.6605860",
language = "English",
volume = "103",
pages = "1173--1181",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323)

AU - Van Herpen, C. M L

AU - Mauer, M. E.

AU - Mesia, R.

AU - Degardin, M.

AU - Jelic, S.

AU - Coens, C.

AU - Betka, J.

AU - Bernier, J.

AU - Remenár, E.

AU - Stewart, J. S.

AU - Preiss, J. H.

AU - Van Den Weyngaert, D.

AU - Bottomley, A.

AU - Vermorken, J. B.

PY - 2010/10/12

Y1 - 2010/10/12

N2 - Background:The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck, showed an improved progression-free and overall survival (OS) with less toxicity when docetaxel (T) was added to cisplatin and 5-fluorouracil (PF) for induction and given before radiotherapy (RT). The impact of the addition of docetaxel on patients health-related quality of life (HRQOL) and symptoms was investigated.Methods:HRQOL was assessed at baseline, at end of cycle 2, and 4, 6, and 9 months after completion of RT using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and the EORTC QLQ Head and Neck Cancer-Specific Module (EORTC QLQ-HN35). The primary HRQOL scale was global HRQOL per protocol.Results: Compliance to HRQOL assessments was 97% at baseline, but dropped to 54% by 6 months. Data were analysed up to 6 months. There was a trend towards improved global HRQOL during the treatment period. At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm, but the low compliance does not allow to draw definitive conclusions. Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2, but to a limited extent.Conclusion:Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.

AB - Background:The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck, showed an improved progression-free and overall survival (OS) with less toxicity when docetaxel (T) was added to cisplatin and 5-fluorouracil (PF) for induction and given before radiotherapy (RT). The impact of the addition of docetaxel on patients health-related quality of life (HRQOL) and symptoms was investigated.Methods:HRQOL was assessed at baseline, at end of cycle 2, and 4, 6, and 9 months after completion of RT using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and the EORTC QLQ Head and Neck Cancer-Specific Module (EORTC QLQ-HN35). The primary HRQOL scale was global HRQOL per protocol.Results: Compliance to HRQOL assessments was 97% at baseline, but dropped to 54% by 6 months. Data were analysed up to 6 months. There was a trend towards improved global HRQOL during the treatment period. At 6 months after the end of RT, global HRQOL was higher in the TPF arm than in the PF arm, but the low compliance does not allow to draw definitive conclusions. Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2, but to a limited extent.Conclusion:Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also seems to improve global HRQOL in a more sustainable manner.

KW - head and neck cancer

KW - HRQOL

KW - symptoms

UR - http://www.scopus.com/inward/record.url?scp=77958002438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958002438&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605860

DO - 10.1038/sj.bjc.6605860

M3 - Article

VL - 103

SP - 1173

EP - 1181

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -